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Abstract
Background: 4-[18F] fluorobenzyl dexetimide (F-DEX) is the first non-subtype selective fluorine-18 labelled tracer for
muscarinic receptors (mAChR) used in humans. A recent first-in-human study found high regional brain uptake with
low variation in normal subjects. Disturbance of mAChR has been reported in Alzheimer’s and Parkinson’s disease,
schizophrenia and depression and various cardiac diseases. The following work assesses the biodistribution, organ
tracer kinetics and radiation dose associated with F-DEX.
Method: Dose calculations were based on activity uptake derived from multiple time point whole body PET CT
imaging and the organ-specific dosimetric S-factors derived from the ICRP 133 standard man and woman
mathematical phantoms. Effective doses were calculated using the latest ICRP tissue weighting factors.
Results: Serial images and time activity curves demonstrate high brain and left ventricular myocardial uptake (5%
and 0.65% of injected activity, respectively) with greater retention in brain than myocardium. The mean effective dose
was in concordance with other 18F labelled tracers at 19.70 ± 2.27 μSv/MBq. The largest absorbed doses were in the
liver (52.91 ± 1.46 μGy/MBq) and heart wall (43.94 ± 12.88 μGy/MBq) for standard man and the liver
(61.66 ± 13.61 μGy/MBq) and lungs (40.93 ± 3.11 μGy/MBq) for standard woman. The absorbed dose to all organs,
most notably, the red bone marrow (20.03 ± 2.89 μGy/MBq) was sufficiently low to ensure no toxicity after
numerous follow-up procedures.
Conclusions: The radiation dose associated with an administration of F-DEX is comparable to that of other 18F
labelled tracers such as FDG (19.0 μSv/MBq) and lower than tracers used for SPECT imaging of muscarinic receptors (
I-DEX 28.5 μSv/MBq). Clinical use would likely result in an effective dose less than 4mSv for the ICRP 133 standard
phantoms after dose optimisation allowing justification for numerous follow-up procedures. Recent results from first
in-human studies and a comparatively low radiation dose make F-DEX an attractive option for future applications of
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imaging muscarinic receptors in the brain. Further investigation of the potential of F-DEX for imaging
parasympathetic innervation of the heart may be warranted.
Keywords: Radiation dosimetry, 4-[18F]fluorobenzyl dexetimide, Muscarinic cholinergic neuroreceptors, Positron
emission tomography
Introduction
The first in-human study of 4-[18F] fluorobenzyl dexe-
timide (F-DEX) has recently shown it to have potential as
a robust tool for detecting variations in muscarinic acetyl-
choline receptors (mAChR) in the brain using hybrid
positron emission tomography and computed tomogra-
phy (PET CT) [1]. However, an accurate analysis of its
dosimetric properties must be made to determine its
safety for patients. It has been shown that a decline in
cholinergic function correlates strongly with the symp-
toms of Alzheimer’s disease [2], and acetyl cholinesterase
inhibitors remain the principle symptomatic treatment
for this condition. Current research into mAChR agonists
aims to develop more effective symptomatic therapy with
less systemic side-effects. Molecular imaging has a signifi-
cant role to play in non-invasive quantification of mAChR
and changes over time. Observing temporal changes of
brain function with PET results in the accrual of relatively
high, though still low level, radiation doses. This empha-
sises the necessity for accurate dosimetry of such tracers
prior to clinical or research use.
There are a number of previously investigated trac-
ers for imaging mAChR in the brain. Iodine-123 labelled
iododexetimide (I-DEX) has proven efficacy for single
photon emission computed tomography (SPECT) imaging
of muscarinic receptors [3–5]. However, tracers labelled
with positron emitting isotopes present a more attractive
alternative owing to the capabilities of PET CT systems
providing superior image quality at reduced radiation
dose. A number of carbon-11-labelled tracers which target
the mAChR have been developed and investigated in ani-
mal and human studies [6–10]; however, an 18F-labelled
analogue presents a much more attractive alternative for
the brain or cardiac imaging due to the short physical half
life of 11C significantly limiting its application.
The following work presents measurements of the biodis-
tribution and dosimetry of F-DEX from five subjects
(three female, twomale) by volumetric analysis of multiple
time point PET acquisitions. Organ-specific dosimetric S-
factors are derived from the International Commission on
Radiological Protection (ICRP) publication 133 phantom
data [11] and are used to calculate the absorbed dose to
a range of organs from which the whole body effective
dose is calculated according to tissue weighting factors
from ICRP publication 103 [12]. A comparison between
the results obtained in this work and other 18F-labelled
tracers is presented and used to make conclusions on the
safety of F-DEX as a tracer. The aim of this study was to
calculate the biodistribution and resultant dosimetry of F-
DEX in a control sample of the population to produce a
conclusive estimate of its associated radiation risk if used
for future investigations.
Methods
Subjects
Five healthy control subjects were recruited for the F-DEX
imaging protocol. Table 1 presents details of all subjects
and the F-DEX administration. Subjects were assessed
by neuropsychological testing and physical examination.
This study was approved by the Austin Health Human
Research Ethics Committee, and written consent was
obtained from all subjects before the imaging studies. No
adverse events related to the study drug were observed or
reported by the subjects following the F-DEX scan.
Tracer synthesis and purification
Production of F-DEX was fully automated using the
iPhase Flexlab synthesis module. The radiosynthe-
sis of F-DEX was achieved by reductive amination
of (S)nordexetimide with 4-[18F]fluorobenzaldehyde.
No-carrier-added 4-[18F]fluoride was produced from
irradiation of [18O]water. [18F]Fluoride was then eluted
to reactor 1 by a mixture of K2CO3 and kryptofix 2.2.2
in a 1:1 solution of acetonitrile/water. The [18F]fluoride
was dried by azeotropic distillation at 90 ◦C using
1 mL of dry acetonitrile. A solution of 4-formyl-
N ,N ,N-trimethylbenzenaminium trifluoromethanesul-
fonate (2.5 mg) in dimethylformamide (DMF) (0.5 ml)
Table 1 Subject details
Subject Sex Age (y) Height (m) Mass (kg) Administered
activity*
(MBq)
1 F 32 1.65 64.3 243
2 F 23 1.72 67.7 246
3 F 36 1.57 68.1 262
4 M 28 1.96 103.6 245
5 M 31 1.84 74.1 246
Mean ± SD 30 ± 4.3 1.75 ± 0.14 75.6 ± 14.4 248.4 ± 6.89
*The radiopharmaceutical was administered intravenously as a 5-ml bolus
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was added to the dried [18F]fluoride, and reactor 1
was then heated at 120 ◦C for 25 min to produce
4-[18F]Fluorobenzaldehyde. Using 600 μL of DMF
containing 12 μL of acetic acid, the reaction mix-
ture was transferred into reactor 2, which was loaded
with NaBH3CN (4.5 mg), (S)nordexetimide (3 mg).
Reactor 2 was then heated to 120 ◦C for 15 min to
form F-DEX by one pot reductive amination between
4-[18F]fluorobenzaldehyde and (S)nordexetimide. The
reaction mixture was purified by C18 Sep-pak and eluted
with 1 mL of acetonitrile followed by high-performance
liquid chromatography (HPLC) purification with a
Gemini Phenomenex 250 ×10 mm semi-preparative
HPLC column using gradient elution technique with
ammonium formate/acetonitrile (0% acetonitrile–45%
acetonitrile over 45 min) as mobile phase. F-DEX was
collected at 48 min into 80 mL of water and refor-
mulated in 10% ethanol/saline using the solid phase
extraction technique. The reformulated F-DEX solu-
tion was then passed through a 0.22 μm filter and
recovered in a sterile vial. The total synthesis time was
140 min.
PET CT protocol
A Philips Ingenuity TF-128 PET CT system was used to
acquire five sets of whole body PET and CT images at
post-injection time points of 0, 20, 60, 100 and 190 min
with each image acquired from the top of the head to the
mid-thigh, and each PET image acquired for 60 s per bed
position with a total scan time of 10 min. Additional PET
and CT brain acquisitions were performed at 120min post
administration for assessment of image quality. All sub-
jects were instructed to void their bladder before enter-
ing the imaging room after which, they were positioned
arms down supine. Whole body CT images were initially
acquired followed immediately by an intravenous admin-
istration of F-DEX at the commencement of PET imaging.
Each subject remained on the bed for the initial 30 min
allowing for a single whole body CT image applicable to
the first two PET images. Subsequent PET images were
preceded by a whole body CT image. All whole body CT
images were acquired at an X-ray tube voltage of 120 kV
and a mean exposure of 22.8 mAs (range, 14–30 mAs)
providing adequate image quality for delineating dosimet-
ric source regions and providing attenuation correction
μ-maps for PET images. The additional brain acquisition
at 120 min post administration consisted of a low-dose
head CT at an X-ray tube voltage of 80 kV and exposure
of 30 mAs followed by a single bed position 20 min PET
acquisition. Four of the five subjects voided their bladder
in the 20 to 60-min and 100 to 190-min intervals, with the
remaining subject voiding in the 60 to 100-min and 100 to
190-min intervals. PET data was reconstructed with the
Philips BLOB-OS-TF reconstruction algorithm, CT atten-
uation correction, simulated scatter correction, randoms
estimates and dead time corrections.
Image analysis for tracer uptake
The subjects PET images were coregistered with their cor-
responding CT images in the quantitative image analysis
environment Pmod for the purposes of defining a volume
of interest (VOI) over each source organ. The fourteen
source organs considered in the dosimetric analysis are
the brain, heart contents, kidneys, large intestine, liver,
lungs, muscle tissue, red marrow, small intestine, spleen,
stomach, thyroid, urinary bladder and remaining tissue.
The left ventricular myocardium was also segmented to
assess whether there is retention relative to blood pool
in the heart chambers but was included in the definition
of heart contents for the dosimetric analysis. The aver-
age activity uptake in a source organ was determined from
the volume weighted activity concentration of the corre-
sponding VOI for eleven of the fourteen source organs
with the exceptions being the red marrow, muscle tis-
sue and remaining tissue. Activity in the red marrow was
inferred from the average activity concentration inside the
vertebrae of the lumbar spine, assuming a red marrow
density of 1 g/cm3 and considering the total mass of red
marrow for ICRP 133 standard man and woman. Uptake
in the muscle tissue and remaining tissue was determined
by defining a VOI over the entire body at each time point,
subtracting the activity measured in each of the other VOI
to determine a residual activity and assigning the fraction
of residual activity to themuscle tissue or remainder tissue
according to their mass. The blood clearance rate was esti-
mated by segmenting the aortic arch and determining the
normalised activity concentration in the delineated vol-
ume. Themean and standard deviation of uptake values in
the organs considered were determined from all five sub-
jects at each time point to determine the pharmacokinetic
properties of F-DEX.
Activity uptake models
For all VOI other than the bladder, the activity uptake as a
function of time was fitted with a least squares regression
to either a sum of two exponentials
A(t) = C0e−αt + C1e−βt (1)
or a delayed uptake and washout model
A(t) = C0
(
1 − e−αt)e−λphyst + C1e−βt (2)
where for both models A(t) describes the total activity A
in the VOI at time t, λphys = ln(2)t1/2 where t1/2 is the half
life of 18F and C0, C1, α, β are free parameters determined
by the regression. Activity in the bladder was assumed to
accumulate as
A(t) = A0,full
(
1 − e−λfillt)e−λphyst (3)
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where A0,full represents the activity at t = 0 of a full blad-
der and λfill is a constant describing the rate at which
the bladder fills. The concentration of tracer in the urine
was assumed to be constant. Upon voiding, the model
assumed instantaneous and total emptying with instanta-
neous refilling. The activity inside each source organ was
assumed to decay according to the physical half life of 18F
after the last time point to ensure the most conservative
estimate to the dosimetric calculations.
Dosimetry
Internal dosimetry was performed according to the for-
mulation presented in the Committee onMedical Internal
Radiation Dose pamphlet 21 [13] which specifies the time
dependent absorbed dose to a target organ as
D(rt ,T) =
∑
rs
A˜(rs,T)S(rt ← rs) (4)
Fig. 1 Coronal projections of F-DEX imaging. Acquisitions at time points t = 0, 20, 60, 100, 190 min post administration of F-DEX for each of the five
subjects studied. Each row displays one subject and each column represents one time point post administration
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where the term A˜(rs,T) is the cumulative activity inside
source organ rs after time T and S(rt ← rs) is the S fac-
tor describing the absorbed dose delivered to the target
organ rt per unit of cumulative activity in source organ rs.
S factors for 18F were derived for standard man and stan-
dard woman from the specific absorbed fraction (SAF)
data complementing ICRP publication 133. The photon
contributions were calculated by linear interpolation of
the ICRP 133 photon SAF data to 511 keV , and the beta
contributions were calculated by numerically integrating
the ICRP 133 electron SAF data over an integral nor-
malised probability distribution of the 18F beta spectrum.
Results
Organ uptake
Figure 1 shows coronal projections of PET images taken
at each time point for each subject studied. It is visu-
ally apparent that the high uptake organs include the
liver, brain, lungs and urinary bladder (Fig. 1). Uptake
in myocardium is also apparent in early images (Fig. 1).
Table 2 lists each segmented organ, the equation number
of the least squares fitted activity uptake model, the asso-
ciated fitting parameters for the averaged activity uptake
models and the cumulative activity normalised by the
administered activity. Figure 2 shows plots of the activity
uptake models for all organs listed in Table 2 except peak
normalised blood clearance with data points and error
bars indicative of the sample mean and sample 95% confi-
dence interval (95% CI) in the VOI activity across all five
subjects. The largest cumulative activities were calculated
for the muscle tissue, remaining tissue, liver, lungs and
brain. The time activity curves in Fig. 2 show fast excretion
from the lungs, spleen and kidneys with persistent reten-
tion in the brain and liver. Myocardial clearance is much
more rapid than brain with little retention at 100 min,
but it is slower than lung and blood clearance as shown
in Fig. 3. Figure 4 shows 4 mm slices through the heart
and 2 mm slices through the brain at time points of 60
and 120 min post administration, respectively. The brain
demonstrates excellent uptake in the striatum, signifi-
cantly less uptake in the thalamus relative to the striatum
and negligible uptake in the cerebellum which is consis-
tent with the known distribution of mAChR in the brain.
Good contrast is observed between the chambers of the
heart and the left ventricular myocardium.
Dosimetry
Dosimetry was performed using each subjects individ-
ual activity uptake data to estimate the distribution of
absorbed doses to organs and whole body effective doses.
Table 2 Biokinetic modelling parameters for delineated regions
Region Activity uptake modela Fit parametersb Cumulative activity
C0 (%) C1 (%) α (min−1) β (min−1) (MBq h/MBq)
Spleen 1 2.517 0.179 0.02624 0.00017 0.02659
Lungs 1 16.064 5.376 0.06423 0.00772 0.16487
Thyroid 1 0.239 0.109 0.09056 0.00909 0.00266
Kidneys 1 1.660 1.400 0.08843 0.00839 0.03360
Heart contents 1 2.470 0.763 0.02277 0.00377 0.04591
Stomach contents 1 0.881 0.0 0.01292 0.0 0.01354
Large intestine 1 0.665 0.0 0.00879 0.0 0.01408
Small intestine 1 1.084 0.0 0.00702 0.0 0.02680
Muscle tissue 1 26.771 0.0 0.00692 0.0 0.65455
Remaining tissue 1 23.314 0.0 0.00708 0.0 0.56611
Blood clearancecd 1 58.62 41.39 0.07824 0.00690 N/A
Myocardium (LV)d 2 0.201 0.630 0.13425 0.02971 0.00872
Red marrow 2 0.983 2.439 0.05047 0.00532 0.09511
Brain 2 2.485 4.072 0.09423 0.00715 0.16301
Liver 2 26.814 8.176 0.01704 0.01360 0.42313
Bladder model A0,full (%) λfill (min−1) void time 1 void time 2
(min) (min)
Bladder 3 6.3034 0.02329 34.92 162.36 0.10400
aNumbering refers to the equation number in the text
bThe parameters specified are applicable over the domain of 0 ≤ t ≤ 190 min
cBlood clearance refers to a peak normalised percentage activity concentration in the blood
dLeft ventricular (LV) myocardium and blood were incorporated into heart contents and remainder tissue in the dosimetric analysis
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Fig. 2 Time-activity curves. The percentage of the initially administered activity as a function of time post injection. Each datum represent the
sample mean and sample 95% CI of all five subjects
The sample mean and sample 95% CI of the whole body
effective dose averaged over the five subjects studied was
calculated to be 19.70 ± 2.27 μSv/MBq using the stan-
dard male and female S factors calculated from ICRP
133 SAF data for male and female subjects, respectively.
Table 3 lists the sample means and 95% CI calculated
over all subjects, male subjects and female subjects.
Averaging the effective doses for ICRP133 standard man
and standard woman separately highlights an effective
dose approximately 15% larger for the standard female.
The organs which receive the largest absorbed dose for
standard man are the liver (52.91 ± 1.46 μGy/MBq),
heart wall (43.94 ± 12.88 μGy/MBq), lungs (42.14 ±
7.16 μGy/MBq), spleen (36.44 ± 7.41 μGy/MBq) and
gallbladder (27.27 ± 0.70 μGy/MBq). The organs which
receive the largest absorbed dose for standard woman
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Fig. 3 Blood clearance comparison. A comparison of tracer clearance from the brain, left ventricular myocardium, lungs and blood indicates optimal
brain imaging likely after 60 min post administration and suggests potential for myocardial imaging between 20 to 60 min post administration
Fig. 4 2 mm brain slices and 4 mm heart slices 120 and 60 min post administration. Good contrast is observed in the brain after 120 min and in the
left ventricular myocardium after 60 min
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Table 3 Effective dose estimates
Effective dose (μSv/MBq)
Sample mean Sample 95% CI Range
Male 17.82 0.96 17.13, 18.51
Female 20.96 2.97 18.91, 24.66
All subjects 19.70 2.27 17.13, 24.66
Female subject effective doses: 19.30, 18.91, 24.66 μSv/MBq
Male subject effective doses: 17.13, 18.51 μSv/MBq
Effective doses calculated using ICRP 103 tissue weighting factors and each individual subjects biokinetic uptake data
are the liver (61.66 ± 13.61 μGy/MBq), lungs (40.93 ±
3.11 μGy/MBq), spleen (39.69 ± 8.29 μGy/MBq), heart
wall (39.33 ± 5.06 μGy/MBq) and thyroid (38.60 ±
28.72 μGy/MBq), respectively. Table 4 lists the sample
mean and sample 95% CI of absorbed doses calculated
from each subject’s organ uptake data for each organ
assigned an ICRP 103 tissue weighting factor in the
ICRP 133 standard male and female phantoms. Dosime-
try appears consistent for both standardman and standard
woman in all organs except the thyroid. Subject 3 as
Table 4 Organ absorbed doses for ICRP 133 standard man and standard woman
Target organs Absorbed dose (μGy/MBq)
Male (N = 2) Female (N = 3)
Lungs 42.14 ± 7.16 40.93 ± 3.11
Stomach wall 17.05 ± 2.97 17.89 ± 4.18
Colon 8.74 ± 0.17 9.16 ± 1.11
Red marrow 14.68 ± 2.67 20.03 ± 2.89
Breast 6.95 ± 0.56 6.71 ± 0.74
Ovaries 11.27 ± 1.24
Testes 3.75 ± 0.07
Thyroid 16.95 ± 2.11 38.60 ± 28.72
Oesophagus 13.49 ± 1.89 13.74 ± 1.63
Urinary bladder wall 23.23 ± 6.37 32.63 ± 4.15
Liver 52.91 ± 1.46 61.66 ± 13.61
Endosteum 7.63 ± 1.20 10.56 ± 1.37
Skin 3.43 ± 0.13 4.00 ± 0.66
Brain 27.35 ± 5.18 33.17 ± 0.44
Salivary glands 4.02 ± 0.47 5.41 ± 0.46
Adrenals 17.99 ± 0.18 22.34 ± 3.84
Extrathoracic tissue 5.59 ± 0.75 6.66 ± 0.63
Gallbladder wall 27.27 ± 0.70 29.44 ± 5.98
Heart wall 43.94 ± 12.88 39.33 ± 5.06
Kidneys 27.24 ± 0.27 31.01 ± 1.88
Lymphatic nodes 9.77 ± 0.45 10.45 ± 1.27
Muscle 7.91 ± 0.10 11.54 ± 0.77
Oral mucosa 4.08 ± 0.50 5.12 ± 0.48
Pancreas 15.44 ± 0.13 14.90 ± 2.54
Prostate 11.19 ± 2.08
Small intestine 9.82 ± 0.74 12.03 ± 1.59
Spleen 36.44 ± 7.41 39.69 ± 8.29
Thymus 9.16 ± 1.51 10.08 ± 0.89
Uterus/cervix 15.72 ± 1.80
Each datum is the sample mean ± sample 95% CI of the organ doses taken over all subjects of the same sex
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Table 5 Comparison of effective whole body doses for 18F tracers found in the literature
Author Tracer Effective dose (μSv/MBq) Number of subjects Measure of error
This work 18F-DEX 19.70 ± 2.27 5 95% CI
ICRP publication 106 [14] 18F-FDG 19.0
O’Keefe et al. [15] 18F-BAY94-9172 14.67 ± 1.39 3 SD
Doss et al. [16] 18F-RGD-K5 17.2 ± 0.6 4 SD
Bottlaender et al. [17] 18F-fluoro-A-85380 19.4 (17.8, 21.8) 3 Range
specified in Table 1 saw a peak thyroid uptake a fac-
tor of seven greater than that of other subjects positively
skewing the female thyroid dose in Table 4.
Discussion
Dose estimates for an administration of F-DEX have been
previously based on biokinetic data from animal stud-
ies with F-DEX or the biokinetic properties of I-DEX
in humans determined from SPECT studies. This study
presents the first PET CT-based dosimetric analysis of
F-DEX in humans. The dosimetric properties of F-DEX
are relatively concordant with those of other 18F labelled
tracers due to the relatively short physical half-life (109.7
min) dominating the effects of biological excretion. A
mean effective dose to ICRP 133 phantoms of 19.70 ±
2.27 μSv/MBq is reported for the cohort studied which
is in excellent concordance with the mean effective dose
of 19.0 μSv/MBq reported for 18F-fluorodeoxyglucose
(FDG) [14]. The excretion and metabolisation of F-DEX
appears similar to that of FDG at a macroscopic level
which is causal in the similarity of their dosimetric prop-
erties. Table 5 presents a comparison of the effective dose
per unit of administered activity for F-DEX and other 18F
-labelled tracers.
The models for organ uptake show significant tracer
metabolism in the liver resulting in relatively large
absorbed doses to both the liver and gallbladder wall.
Significant excretion through the renal system is also
observed resulting in high activity accumulation in the
urinary bladder and relatively large absorbed doses to the
kidneys, adrenal glands and urinary bladder wall. The
administered dose of 250 MBq produced excellent diag-
nostic image quality in the brain leaving room for dose
optimisation to likely reduce the effective whole body dose
from the PET examination to below 4 mSv. In compari-
son, I-DEX for SPECT imaging of mAChR produces an
effective dose of 28.5 μSv/MBq [18]. The absorbed dose
to the red bone marrow for a 250 MBq administration of
F-DEX is 5.01±0.72 mGy for standard woman (3.67±0.67
for standard man) allowing multiple examinations whilst
remaining below the ICRP specified annual threshold for
red marrow of 250 mGy [19]. A blood sampling approach
to red marrow dosimetry was not used due to its inac-
curacy for tracers showing specific uptake in the bones
or bone marrow. Blood sampling may have provided a
more accurate measurement of the blood clearance rate;
however, this was considered negligible relative to the
additional burden to subjects and staff. The absorbed
dose to the kidneys for the same administration is 7.75 ±
0.47 mGy for standard woman (6.81 ± 0.07 mGy for stan-
dard man) which will ensure accumulated dose remains
well below the ICRP specified limit of 7 Gy for observable
effects [19] in the event of numerous follow-up investiga-
tions. Potential improvements in the accuracy of bladder
dosimetry from urine sampling were deemed negligible
relative to the additional workload required for handling
and analysing samples. This study has also demonstrated
good uptake of tracer in the myocardium with slower
clearance than the blood and lungs suggesting F-DEXmay
be useful for assessing parasympathetic innervation of the
heart.
Conclusions
Themean effective whole body dose to ICRP 133 standard
male and standard female phantoms from an administra-
tion of F-DEX was found to be 19.70 ± 2.27 μSv/MBq
from a sample of five subjects; two male and three female.
The effective dose associated with F-DEX is compara-
ble to other 18F labelled tracers and superior to that of
the SPECTmAChR tracer I-DEX, presenting an attractive
alternative to imagingmAChR from a radiation protection
and image quality perspective.
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